|
[1]
|
曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
|
|
[2]
|
Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462. [Google Scholar] [CrossRef]
|
|
[3]
|
Zhang, Y., Xu, Y., Ma, W., Wu, H., Xu, G., Chekhonin, V.P., Peltzer, K., Wang, X., Wang, G. and Zhang, C. (2022) The Homogeneity and Heterogeneity of Occurrence, Characteris-tics, and Prognosis in Hepatocellular Carcinoma Patients with Synchronous and Metachronous Bone Metastasis. Journal of Cancer, 13, 393-400. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Guo, X., Xu, Y., Wang, X., Lin, F., Wu, H., Duan, J., et al. (2019) Ad-vanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estmation. Medi-cal Science Monitor: International Medical Journal of Experimental and Clinical Research, 25, 1105-1112. [Google Scholar] [CrossRef]
|
|
[5]
|
Lu, Y., Hu, J., Lin, X. and Li, X. (2017) Bone Metastases from Hepatocellular Carcinoma: Clinical Features and Prognostic Factors. Hepatobiliary & Pancreatic Diseases International, 16, 499-505. [Google Scholar] [CrossRef]
|
|
[6]
|
Roodman, G. (2004) Mechanisms of Bone Metastasis. The New England Journal of Medicine, 350, 1655-1664. [Google Scholar] [CrossRef]
|
|
[7]
|
Paget, S. (1889) The Distribution of Secondary Growths in Cancer of the Breast. The Lancet, 133, 571-573. [Google Scholar] [CrossRef]
|
|
[8]
|
Guo, X., Sun, T., Yang, M., Li, Z., Li, Z. and Gao, Y. (2013) Prognostic Value of Combined Aquaporin 3 and Aquaporin 5 Overexpression in Hepatocellular Carcinoma. Bio-Med Research International, 2013, Article ID: 206525. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Pelagalli, A., Nardelli, A., Fontanella, R. and Zannetti, A. (2016) Inhibi-tion of AQP1 Hampers Osteosarcoma and Hepatocellular Carcinoma Progression Mediated by Bone Marrow-Derived Mesenchymal Stem Cells. International Journal of Molecular Sciences, 17, Article No. 1102. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ning, J., Ye, Y., Bu, D., Zhao, G., Song, T., Liu, P., Yu, W., Wang, H., Li, H., Ren, X., Ying, G., Zhao, Y. and Yu, J. (2021) Imbalance of TGF-β1/BMP-7 Pathways Induced by M2-Polarized Macrophages Promotes Hepatocellular Carcinoma Aggressiveness. Molecular Therapy, 29, 2067-2087. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zeng, S., Zhang, Y., Ma, J., Deng, G., Qu, Y., Guo, C., Han, Y., Yin, L., Cai, C., Li, Y., Wang, G., Bonkovsky, H.L. and Shen, H. (2017) BMP4 Promotes Metastasis of Hepatocel-lular Carcinoma by an Induction of Epithelial-Mesenchymal Transition via Upregulating ID2. Cancer Letters, 390, 67-76. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Ponting, C.P., Oliver, P.L. and Reik, W. (2009) Evolution and Functions of Long Noncoding RNAs. Cell, 136, 629-641. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zhang, L., Niu, H., Ma, J., Yuan, B.Y., Chen, Y.H., Zhuang, Y., Chen, G.W., Zeng, Z.C. and Xiang, Z.L. (2019) The Molecular Mechanism of LncRNA34a-Mediated Regulation of Bone Metastasis in Hepatocellular Carcinoma. Molecular Cancer, 18, 120. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ma, Z.J., Wang, Y., Li, H.F., Liu, M.H., Bi, F.R., Ma, L., Ma, H. and Yan, H.L. (2020) LncZEB1-AS1 Regulates Hepatocellular Carcinoma Bone Metastasis via Regulation of the miR-302b-EGFR-PI3K-AKT Axis. Journal of Cancer, 11, 5118-5128. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Huang, Z., Chu, L., Liang, J., Tan, X., Wang, Y., Wen, J., Chen, J., Wu, Y., Liu, S., Liao, J., Hou, R., Ding, Z., Zhang, Z., Liang, H., Song, S., Yang, C., Zhang, J., Guo, T., Chen, X. and Zhang, B. (2021) H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging mi-croRNA 200b-3p. Hepatology, 74, 214-232. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Shi, Y., Qin, N., Zhou, Q., Chen, Y., Huang, S., Chen, B., Shen, G. and Jia, H. (2017) Role of IQGAP3 in Metastasis and Epithelial-Mesenchymal Transition in Human Hepatocellular Carcino-ma. Journal of Translational Medicine, 15, 176. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Zhang, S., Xu, Y., Xie, C., Ren, L., Wu, G., Yang, M., Wu, X., Tang, M., Hu, Y., Li, Z., Yu, R., Liao, X., Mo, S., Wu, J., Li, M., Song, E., Qi, Y., Song, L. and Li, J. (2020) RNF219/α-Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications. Advanced Science, 8, Article ID: 2001961. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Coleman, R.E., Croucher, P.I., Padhani, A.R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R and Costa, L. (2020) Bone Metastases. Nature Reviews Disease Primers, 6, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Shen, G., Deng, H., Hu, S. and Jia, Z. (2014) Comparison of Choline-PET/CT, MRI, SPECT, and Bone Scintigraphy in the Diagnosis of Bone Metastases in Patients with Prostate Cancer: A Meta-Analysis. Skeletal Radiology, 43, 1503-1513. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Nakamoto, Y., Cohade, C., Tatsumi, M., Hammoud, D. and Wahl, R.L. (2005) CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examina-tion. Radiology, 237, 627-634. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Coleman, R., Hadji, P., Body, J.J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., Jordan, K. and ESMO Guidelines Committee (2020) Bone Health in Cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 31, 1650-1663. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
He, J., Zeng, Z.C., Xiang, Z.L. and Yang, P. (2014) Mass Spectrometry-Based Serum Peptide Profiling in Hepatocellular Carcinoma with Bone Metastasis. World Journal of Gas-troenterology, 20, 3025-3032. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Hu, J.G., Lu, Y. and Lin, X.J. (2020) En Bloc Lumpectomy of T12 Vertebra for Progressive Hepatocellular Carcinoma Metastases Following Liver Transplantation: A Case Report. Medi-cine, 99, e18756. [Google Scholar] [CrossRef]
|
|
[24]
|
Chen, L., Wang, Z., Song, S., Sun, T., Ren, Y., Zhang, W., Wang, M., Liu, Y. and Zheng, C. (2021) The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. Journal of Oncology, 2021, Article ID: 5190611. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J. and SHARP Investigators Study Group (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-90. [Google Scholar] [CrossRef]
|
|
[26]
|
Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., Blanc, J.F., Vogel, A., Komov, D., Evans, T.R.J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M. and Cheng, A.L. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173. [Google Scholar] [CrossRef]
|
|
[27]
|
None (2021) IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer. M2 Press-WIRE.
|